Sugi Predict

Sugi Predict / Compounds / Succedaneaflavanone

Succedaneaflavanone

Succedaneaflavanone

SCHEMBL615879

O=C1CC(c2ccc(O)cc2)Oc2cc(O)c(-c3c(O)cc4c(c3O)C(=O)CC(c3ccc(O)cc3)O4)c(O)c21

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.78
▸ MEN1 O00255 3/20 0.78
▸ POLB P06746 3/20 0.78
▸ APEX1 P27695 2/20 0.78
▸ RECQL P46063 2/20 0.78
▸ CACNA1B Q00975 1/20 0.78
▸ APBA1 Q02410 1/20 0.78
▸ MCL1 Q07820 1/20 0.78
▸ CTDSP1 Q9GZU7 1/20 0.78
▸ L3MBTL1 Q9Y468 1/20 0.78
▸ CYP19A1 P11511 5/20 0.77
▸ CYP3A4 P08684 4/20 0.77
▸ ESR1 P03372 3/20 0.77
▸ CYP1A1 P04798 3/20 0.77
▸ CYP1A2 P05177 3/20 0.77
▸ CYP2C19 P33261 3/20 0.77
▸ CYP1B1 Q16678 3/20 0.77
▸ HSD17B10 Q99714 3/20 0.77
▸ TDP1 Q9NUW8 2/20 0.77
▸ CYP2C9 P11712 2/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL617168 0.94 KMT2A (0.70) KMT2AMEN1POLBAPEX1RECQL
SCHEMBL476289 0.91 PLK1 (0.80) KMT2AMEN1POLBAPEX1RECQL
SCHEMBL476401 0.91 PLK1 (0.80) KMT2AMEN1POLBAPEX1RECQL
SCHEMBL30064298 0.91 PLK1 (0.80) KMT2AMEN1POLBAPEX1RECQL
SCHEMBL24406183 0.88 KMT2A (1.00) KMT2AMEN1POLBAPEX1RECQL
SCHEMBL29099768 0.88 KMT2A (1.00) KMT2AMEN1POLBAPEX1RECQL
SCHEMBL29906199 0.88 KMT2A (1.00) KMT2AMEN1POLBAPEX1RECQL
Naringenin SCHEMBL20570 0.87 CYP19A1 (1.00) KMT2AMEN1POLBAPEX1RECQL
Naringenin SCHEMBL1048136 0.87 CYP19A1 (1.00) KMT2AMEN1POLBAPEX1RECQL
Naringenin SCHEMBL29351357 0.87 CYP19A1 (1.00) KMT2AMEN1POLBAPEX1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103221056-A Electronically Modified Reaction Intermediates MARKOU DEMETRIOS 2013-07-24 — — CN claimed
EP-2603225-A2 ELECTRONICALLY MODIFIED REACTION INTERMIDEATES Markou, Demetrios (US) 2013-06-19 — — EP claimed
WO-2012024196-A2 A NOVEL METHOD FOR CREATING, SUSPENDING AND STABILIZING ELECTRONICALLY MODIFIED REACTION INTERMIDEATES MARKOU DEMETRIOS (US) 2012-02-23 — — WO claimed
US-20120039796-A1 Novel method for creating, suspending and stabilizing electronically modified oxygen derivatives, along with creating, suspending and stabilizing electronically modified reaction intermediates, in a bio compatible fluorocarbon suspension, for the purpose of inducing a cascading immune response in mammalian patients MARKOU DEMETRIOS (US) 2012-02-16 — — US claimed
US-20020068757-A1 Biflavanoids and derivatives thereof as antiviral agents ADVANCED LIFE SCIENCES, INC. 2002-06-06 — — US claimed
US-6399654-B1 ADMINISTERING MIXTURE OF VIRICIDE AND BIOFLAVANOID ADVANCED LIFE SCIENCES, INC. 2002-06-04 — — US claimed
WO-1998046238-A1 BIFLAVINOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS, ALONE OR IN COMBINATION WITH AT LEAST ONE KNOWN ANTIVIRAL AGENT MEDICHEM RESEARCH, INC. (US) 1998-10-22 — — WO claimed
EP-0833631-A1 BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS MEDICHEM RESEARCH, INC. (US) 1998-04-08 — — EP claimed
WO-1997000679-A1 BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS MEDICHEM RESEARCH, INC. (US) 1997-01-09 — — WO claimed
CN-103702675-B Rhus verniciflua Stokes extract with increased content of active flavonoid compounds and its preparation method AZI有限公司 2017-06-23 — — CN disclosed
EP-2604274-B1 RHUS VERNICIFLUA STOKES EXTRACT HAVING INCREASED CONTENT OF ACTIVE FLAVONOID COMPOUND AND METHOD FOR PREPARING SAME AZI COMPANY LTD (KR) 2016-07-13 — — EP disclosed
US-8859014-B2 Method of converting fustin to fisetin AZI COMPANY LTD. (KR) 2014-10-14 — — US disclosed
CN-103702675-A Rhus verniciflua Stokes extract with increased content of active flavonoid compounds and its preparation method AZI COMPANY LTD 2014-04-02 — — CN disclosed
US-20140031567-A1 Method of Converting Fustin to Fisetin AZI COMPANY LTD. (KR) 2014-01-30 — — US disclosed
US-5773462-A INFLUENZA THERAPY MEDICHEM RESEARCH, INC. (US) 1998-06-30 — — US disclosed
US-5773462-A INFLUENZA THERAPY MEDICHEM RESEARCH, INC. (US) 1998-06-30 — — US disclosed
EP-0833631-A1 BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS MEDICHEM RESEARCH, INC. (US) 1998-04-08 — — EP disclosed
EP-0833631-A1 BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS MEDICHEM RESEARCH, INC. (US) 1998-04-08 — — EP disclosed
WO-1997000679-A1 BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS MEDICHEM RESEARCH, INC. (US) 1997-01-09 — — WO disclosed
WO-1997000679-A1 BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS MEDICHEM RESEARCH, INC. (US) 1997-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068757-A1 Biflavanoids and derivatives thereof as antiviral agents HK2, GYS2, HK1 KMT2A 463/4885MEN1 836/4885POLB 3037/4885
US-20140031567-A1 Method of Converting Fustin to Fisetin FUS, RFTN1, HRAS KMT2A 1133/4885MEN1 852/4885POLB 833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.